Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Adoption of New eGFR Equations in U.S. Clinical Laboratories

By Mar. 2022, most U.S. state clinical laboratories were aware of revised equations for estimating glomerular filtration rates (eGFRs) as adopted in Sept. 2021 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), a study shows. About one-third of labs had adopted the equations, and nearly half of the others planned to do so during 2022.

The new equations eliminated race-adjustment factors, including one based on creatinine (2021 CKD-EPI creatinine) and one based on creatinine and cystatin C (2021 CKD-EPI creatinine–cystatin C), the authors report. In Mar. 2022, the College of American Pathologists surveyed clinical laboratory staff or directors across the U.S., 3 of its territories, and 51 other countries. Results for the U.S. states showed the following for 4,593 surveys: “Of US respondents, 76.9% reported being aware of the 2021 CKD-EPI equations and 30.3% reported that they already adopted the 2021 CKD-EPI creatinine equation. Of the responding laboratories that had not yet adopted the 2021 CKD-EPI creatinine equation, 21.6% planned to adopt the equation before July 1, 2022, 10.7% between July 1 and December 31, 2022, 2.2% in 2023 or later, and 58.4% were unsure regarding future plans.

“Of US respondents, 3.4% reported that they already adopted the 2021 CKD-EPI creatinine–cystatin C equation, 8.0% reported that they planned to adopt it, 32.0% reported that they did not plan to adopt it, and 56.7% were unsure. The 3 most common barriers to adoption of the 2021 CKD-EPI creatinine–cystatin C equation were limited cystatin C testing options, cost of testing, and staffing resources.”

Source: JAMA